Trial Profile
South Australian Meningococcal B Vaccine Herd Immunity Study
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 07 Sep 2023
Price :
$35
*
At a glance
- Drugs Meningococcal vaccine group B OMV Novartis (Primary)
- Indications Meningococcal group B infections
- Focus Therapeutic Use
- Acronyms B Part of It
- 15 Feb 2021 Results assessing vaccine impact of 4CMenB on serogroup B invasive meningococcal disease in16-19 years adolescents, published in the Clinical Infectious Diseases
- 22 Jul 2020 Results (n=30,522) assessing the safety profile of two doses of 4CMenB in adolescents, published in the Vaccine
- 24 May 2020 Results (n=913) evaluaing Impact of meningococcal B (4CMenB) vaccine on pharyngeal Neisseria meningitidis carriage density and persistence in adolescents, published in the Clinical Infectious Diseases